Arvelle Therapeutics raises USD 180 million in Series A financing
A global syndicate of investors led by LSP and including NovaQuest, BRV Capital Management, Andera Partners, and H.I.G. BioHealth Partners supported new company Arvelle Therapeutics with a USD 180 million financing to acquire the exclusive rights from Korean SK Biopharmaceuticals to develop and commercialise cenobamate in Europe.
VISCHER advised Arvelle Therapeutics as Swiss Counsel. The VISCHER team included Dr. Adrian Dörig (Partner, Banking & Finance), Seraina Jenny-Tsering (Managing Associate, Banking & Finance), Ruben Masar (Senior Associate, Corporate) and Christoph Niederer (Partner, Tax).